BACKGROUND: Although variants in the transcription factor 7-like 2 (TCF7L2) gene are consistently associated with impaired fasting glucose (IFG) in Caucasians, data from large population-based studies of African Americans are lacking. Moreover, few studies have investigated the effects of TCF7L2 on IFG in the context of metabolic risk factors for diabetes. METHODS: We investigated the association between the TCF7L2 rs7903146 polymorphism and incident IFG defined as fasting serum glucose levels of 100-125 mg/dL (5.6-6.9 mmol/L) in 1377 African American and 5152 Caucasian participants without diabetes and IFG at intake who participated in the Atherosclerosis Risk in Communities (ARIC) Study from 1987 to 1989 and were followed for 9 years. RESULTS: Incident IFG was identified in 810 (58.8%) African American and 2652 (51.5%) Caucasian participants. Compared to homozygous CC Caucasian individuals, heterozygous CT [hazard ratio (HR) = 1.09 (95% CI = 1.03-1.15)] and homozygous TT [1.18 (1.05-1.33)] individuals had significantly higher risk of developing IFG over 9-year follow-up. The association between rs7903146 and IFG risk was stronger in Caucasians with obesity [HR(CTvs.CC) = 1.28 (1.12, 1.47); HR(TTvs.CC) = 1.65 (1.25, 2.17)] or high triglycerides [HR(CTvs.CC) = 1.31(1.10, 1.56); HR(TTvs.CC) = 1.72 (1.21, 2.43)]. No association of the TCF7L2 rs7903146 polymorphism and incident IFG was noted in African Americans. CONCLUSIONS: Our study replicates the association between rs7903146 and IFG risk in a population-based, longitudinal cohort of Caucasians but not in African Americans. For the first time, our study provides evidence for interactions between TCF7L2 and metabolic risk factors on the occurrence of IFG in Caucasians. Copyright (c) 2010 John Wiley & Sons, Ltd.
BACKGROUND: Although variants in the transcription factor 7-like 2 (TCF7L2) gene are consistently associated with impaired fasting glucose (IFG) in Caucasians, data from large population-based studies of African Americans are lacking. Moreover, few studies have investigated the effects of TCF7L2 on IFG in the context of metabolic risk factors for diabetes. METHODS: We investigated the association between the TCF7L2rs7903146 polymorphism and incident IFG defined as fasting serum glucose levels of 100-125 mg/dL (5.6-6.9 mmol/L) in 1377 African American and 5152 Caucasian participants without diabetes and IFG at intake who participated in the Atherosclerosis Risk in Communities (ARIC) Study from 1987 to 1989 and were followed for 9 years. RESULTS: Incident IFG was identified in 810 (58.8%) African American and 2652 (51.5%) Caucasian participants. Compared to homozygous CC Caucasian individuals, heterozygous CT [hazard ratio (HR) = 1.09 (95% CI = 1.03-1.15)] and homozygous TT [1.18 (1.05-1.33)] individuals had significantly higher risk of developing IFG over 9-year follow-up. The association between rs7903146 and IFG risk was stronger in Caucasians with obesity [HR(CTvs.CC) = 1.28 (1.12, 1.47); HR(TTvs.CC) = 1.65 (1.25, 2.17)] or high triglycerides [HR(CTvs.CC) = 1.31(1.10, 1.56); HR(TTvs.CC) = 1.72 (1.21, 2.43)]. No association of the TCF7L2rs7903146 polymorphism and incident IFG was noted in African Americans. CONCLUSIONS: Our study replicates the association between rs7903146 and IFG risk in a population-based, longitudinal cohort of Caucasians but not in African Americans. For the first time, our study provides evidence for interactions between TCF7L2 and metabolic risk factors on the occurrence of IFG in Caucasians. Copyright (c) 2010 John Wiley & Sons, Ltd.
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: Hypertension Date: 2003-12-01 Impact factor: 10.190
Authors: Olli T Raitakari; Tapani Rönnemaa; Risto Huupponen; Liisa Viikari; Meng Fan; Jukka Marniemi; Nina Hutri-Kähönen; Jorma S A Viikari; Terho Lehtimäki; Terho Lehtimäkimd Journal: Diabetes Care Date: 2007-05-31 Impact factor: 19.112
Authors: Stéphane Cauchi; Younes El Achhab; Hélène Choquet; Christian Dina; Franz Krempler; Raimund Weitgasser; Chakib Nejjari; Wolfgang Patsch; Mohamed Chikri; David Meyre; Philippe Froguel Journal: J Mol Med (Berl) Date: 2007-05-03 Impact factor: 5.606
Authors: Yu Yan; Kari E North; Christie M Ballantyne; Frederick L Brancati; Lloyd E Chambless; Nora Franceschini; Gerardo Heiss; Anna Kottgen; James S Pankow; Elizabeth Selvin; Suzanne L West; Eric Boerwinkle Journal: Diabetes Date: 2008-10-17 Impact factor: 9.461
Authors: Jason H Karnes; Yan Gong; Michael A Pacanowski; Caitrin W McDonough; Meghan J Arwood; Taimour Y Langaee; Carl J Pepine; Julie A Johnson; Rhonda M Cooper-Dehoff Journal: Pharmacogenet Genomics Date: 2013-12 Impact factor: 2.089
Authors: Yann C Klimentidis; Dominick J Lemas; Howard H Wiener; Diane M O'Brien; Peter J Havel; Kimber L Stanhope; Scarlett E Hopkins; Hemant K Tiwari; Bert B Boyer Journal: J Diabetes Date: 2013-10-29 Impact factor: 4.006
Authors: Danielle M Greenawalt; Solveig K Sieberts; Marilyn C Cornelis; Cynthia J Girman; Hua Zhong; Xia Yang; Justin Guinney; Lu Qi; Frank B Hu Journal: Am J Epidemiol Date: 2012-08-02 Impact factor: 4.897
Authors: Sabrina van der Kroef; Raymond Noordam; Joris Deelen; Abimbola A Akintola; Steffy W M Jansen; Iris Postmus; Carolien A Wijsman; Marian Beekman; Simon P Mooijaart; P Eline Slagboom; Diana van Heemst Journal: PLoS One Date: 2016-02-25 Impact factor: 3.240
Authors: Małgorzata Wrzosek; Ada Sawicka; Michał Wrzosek; Paweł Piątkiewicz; Marek Tałałaj; Grażyna Nowicka Journal: Arch Med Sci Date: 2017-11-17 Impact factor: 3.318